Security key
76155X118
Revolution Medicines, Inc. - *W EXP 12/17/202 (RVMDW)
CUSIP: 76155X118
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / *W EXP 12/17/202
- Total 13F shares
- 9,989,935
- Total 13F value
- $93,038,997
- Share change
- -56,805
- SEC-reported price per share
- $9.38
- Number of holders
- 20
- Value change
- +$7,831,498
- Number of buys
- 5
- Number of sells
- 7
Report period
Q2 2026
Institutions
20
Top holders
10
RVMDW full security history
Ownership snapshot
Full 13F holder table
Revolution Medicines, Inc. SEC filings
Revolution Medicines, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of RVMDW - Revolution Medicines, Inc. - *W EXP 12/17/202 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Farallon Capital Partners...
Disclosed value leader
FARALLON CAPITAL MANAGEME...
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 7.5%
13D/G row: Farallon Capital Partners, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Farallon Capital Partners, L.P. leads the comparable SEC ownership view at 7.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Farallon Capital Partners, L.P.'s linked filing trail.
Comparable ownership
Top 5
Farallon Capital Partners, L.P.
7.5%
FARALLON CAPITAL MANAGEMENT, L.L.C.
6.4%
BlackRock, Inc.
5.7%
BAKER BROS. ADVISORS LP
5.3%
Janus Henderson Group Ltd.
5.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Farallon Capital Partners, L.P. |
13D/G
Dapice Joshua J.
|
7.5%
|
$1,499,170,464
14,596,149 shares
|
+$137,025,822 | 31 Dec 2025 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13D/G
13F
Company
|
6.4%
|
$2,566,879,557
13,564,149 shares
|
$0 | 30 Jun 2026 |
| BlackRock, Inc. |
13D/G
13F
Company
|
5.7%
|
$2,285,077,256
12,201,395 shares
|
+$712,072,458 | 30 Jun 2026 |
| BAKER BROS. ADVISORS LP |
13D/G
13F
Company
|
5.3%
|
$2,165,540,879
11,443,357 shares
|
+$376,209,120 | 30 Jun 2026 |
| Janus Henderson Group Ltd. |
13D/G
13F
Company
|
5.1%
|
$2,031,708,080
10,736,145 shares
|
+$183,496,377 | 30 Jun 2026 |
| FMR LLC |
13F
13D/G
Company
|
5%
from 13D/G
|
$823,154,497
8,464,314 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
20
Shares
9,989,935
Rows available
20
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
21
Q2 2026 holders
20
Holder diff
-1
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|